Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
| dc.rights.license | open | en_US |
| dc.contributor.author | DAIEN, V. | |
| dc.contributor.author | FINGER, R. P. | |
| dc.contributor.author | TALKS, J. S. | |
| dc.contributor.author | MITCHELL, P. | |
| dc.contributor.author | WONG, T. Y. | |
| dc.contributor.author | SAKAMOTO, T. | |
| dc.contributor.author | ELDEM, B. M. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | KOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535 IDREF: 028739272 | |
| dc.date.accessioned | 2021-03-22T09:59:48Z | |
| dc.date.available | 2021-03-22T09:59:48Z | |
| dc.date.issued | 2021-10-21 | |
| dc.identifier.issn | 0007-1161 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26752 | |
| dc.description.abstractEn | The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD).A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD.The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens.RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.title.en | Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence | |
| dc.title.alternative | Br J Ophthalmol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1136/bjophthalmol-2020-317434 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 33130553 | en_US |
| bordeaux.journal | The British Journal of Ophthalmology | en_US |
| bordeaux.volume | 105 | |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 11 | |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | LEHA_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03176168 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-03-22T09:59:53Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=The%20British%20Journal%20of%20Ophthalmology&rft.date=2021-10-21&rft.volume=105&rft.issue=11&rft.eissn=0007-1161&rft.issn=0007-1161&rft.au=DAIEN,%20V.&FINGER,%20R.%20P.&TALKS,%20J.%20S.&MITCHELL,%20P.&WONG,%20T.%20Y.&rft.genre=article |
